ropren facts, page-18

Marcj- it is clearly a mistake for SLA to seek TGA approval when it wishes to market the product in Russia and New Zealand. If SLA share buyers are buying the shares to get the product it is an unnecessary step, hop in a plane go to the supply in NZ, see a real country and get over your liver problems. For share buyers we will strongly reccommend that SLA stay well away from expensive and unnecessary Australian and US trials that will not assist marketing in the chosen markets.

Australia is not the centre of the universe except for metals supply, clearly not a significant market for liver recovery medicines.

And finally persons with hepatitis and early Cirrhosis symptoms who hear of this potential solution having no other realistic solution WILL fly to NZ and won't wait for the unneessary TGA approval. Their choices are more pragmatic